首页> 外国专利> TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB

TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB

机译：HER2XCD3双特异性抗体与抗-HER2 MAB联合治疗癌症

页面导航

摘要
著录项
相似文献

摘要

The present invention provides methods of treating of HER2-positive cancers (such as HER2- positive breast cancer and HER2-positive gastric cancers) using HER2 antibodies, such as a combination of a HER2 T cell-dependent bispecific antibody (TDB) with an additional HER2 antibody (e.g., trastuzumab).

机译：本发明提供使用HER2抗体治疗HER2阳性癌症（例如HER2阳性乳腺癌和HER2阳性胃癌）的方法，例如HER2T细胞依赖性双特异性抗体（TDB）与其他抗体的组合HER2抗体（例如，曲妥珠单抗）。 展开▼

著录项

公开/公告号WO2020186176A1

专利类型

公开/公告日2020-09-17

原文格式PDF

申请/专利权人 GENENTECH INC.;F.HOFFMANN-LA ROCHE AG;
展开▼

申请/专利号WO2020US22665

发明设计人 JUNTTILA TEEMU T.;LUTZKER STUART;
展开▼

申请日2020-03-13

分类号C07K16/32;C07K16/28;A61P35;

国家 WO

入库时间 2022-08-21 11:09:26

相似文献

专利

外文文献

中文文献

1. 用HER2XCD3双特异性抗体联合抗HER2 MAB治疗癌症 [P] . 中国专利： CN113631578A . 2021-11-09

2. 一种双特异性抗体HER2XCD3的构建及应用 [P] . 中国专利： CN104829728B . 2019.03.12

3. TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB [P] . EP3938403A1 . 2022-01-19

机译：用HER2XCD3双特异性抗体治疗癌症与抗HER2 mAb的组合

4. Treatment of cancer with HER2XCD3 bispecific antibody and anti-HER2 MAB in combination [P] . KR20210141555A . 2021-11-23

机译：用HER2XCD3双特异性抗体治疗癌症和抗HER2MAb组合

5. method of treating a human individual who has cancer, anti-cd25 antibody, use of an anti-cd25 antibody, combination of an anti-cd25 antibody, kit for use in the treatment of cancer, pharmaceutical composition, combination, bispecific antibody, method of cancer treatment, and method of depleting regulatory t cells in an individual [P] . BR112019017017A2 . 2020-04-14

机译：治疗患有癌症的人的方法，抗cd25抗体，抗cd25抗体的用途，抗cd25抗体的组合，用于治疗癌症的试剂盒，药物组合物，组合，双特异性抗体，癌症治疗，以及消耗个体调节性t细胞的方法

1. The immunophenotypic changes and clinical effectiveness after treatment of cancer patients with infusion of human peripheral blood lymphocytes stimulated by anti-CD28 and anti-CD80 monoclonal antibodies in combination with radiotherapy and chemotherapy [J] . JUN, JIA, LI, 中华微生物学和免疫学：英文版 . 2005,第002期

2. Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study [J] . Wei Zhao, Li Bian, Tao Wang, 中国癌症研究（英文版） . 2020,第003期

3. Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach [J] . Tkaczyk C., Kasturirangan S., Minola A., Antimicrobial agents and chemotherapy. . 2017,第8期

4. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment [J] . Shengnan Yu, Qian Liu, Xinwei Han, Experimental Hematology Oncology . 2017,第1期

5. Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients [J] . Ulka Vaishampayan, Archana Thakur, Ritesh Rathore, Prostate cancer . 2015,第Null期

6. The Benefits of Bispecific mAb-square Antibodies Targeting EGFR and HGF [C] . Melanie Medcalf, Kin-Mei Leung, Samine Isaac, Protein Engineering Summit. . 2018

7. Genetically Engineered Bispecific Antibodies for Cancer Pretargeting using the Irreversible Probe Capturing mAb 2D12.5 G54C. [D] . Beck, Heather Elizabeth. 2012

8. Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach [O] . C. Tkaczyk, S. Kasturirangan, A. Minola, 2017

9. Endogenous Cytokine Responses and Unexpected Survival in a Phase I Trial Using Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells (HER2 BATs) for Treatment of Women with Stage III Breast Cancer [O] . Archana Thakur, Lawrence G Lum, Gerald A Colvin, 2019

10. Treatment of Breast Cancer With Antibodies Against DR4 and DR5 Receptors in Combination With Chemotherapy [R] . Buchsbaum, D. J. 2005

1. Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis [J] . Li Yang ,Xian-Zhe Dong ,Xiao-Xuan Xing . 世界胃肠肿瘤学杂志：英文版（电子版） . 2020,第11期

2. Antibody gene therapy: an attractive approach for the treatment of cancers and other chronic diseases [J] . Dexian Zheng . 细胞研究：英文版 . 2007,第4期

3. Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model [J] . Mieko Yanagisawa ,Keigo Yorozu ,Mitsue Kurasawa . 癌症治疗（英文） . 2013,第7期

4. 抗O型口蹄疫病毒VP1蛋白单克隆抗体(Mab)的制备及鉴定 [C] . 李方方 ,闫若潜 ,马震原 . 中国畜牧兽医学会生物技术学分会暨中国免疫学会兽医免疫分会第十二次学术研讨会 . 2016

5. 基因工程抗HER2/neu ×抗CD16双特异性抗体的构建、表达及其功能的初步研究 [A] . 解志刚 . 2004